Research Article
Prognostic Factors of Radiofrequency Ablation plus Systemic Chemotherapy for Unresectable Colorectal Cancer with Liver Metastasis
Table 2
Estimated survival times by potential prognostic factor.
| Variables | | Median survival, months (95% CI) | value |
| Sex | Male () | 35 (27–42) | 0.155 | Female () | 32 (27–39) | | Age | <40 () | 40 (21–58) | 0.66 | 40–60 () | 32 (25–38) | | >60 () | 37 (31–42) | | Number of liver lesions | 1–3 () | 41 (35–48) | 0.008 | 4–5 () | 24 (19–29) | | Size of the largest liver lesion | ≤3 cm () | 38 (35–51) | 0.026 | >3 cm () | 30 (15–44) | | Sum of the diameter of liver lesions | <5 cm () | 43 (35–51) | 0.011 | 5–10 cm () | 30 (25–36) | | >10 cm () | 22 (16–27) | | Primary cancer | Colon () | 40 (33–47) | 0.263 | Rectum () | 28 (23–33) | | Type of metastasis | Synchronous () | 32 (28–35) | 0.69 | Metachronous () | 35 (29–50) | | Chemo regimen | FOLFOX–4 () | 32 (23–46) | 0.346 | FOLFIRI () | 28 (23–33) | | ECOG performance status | 0 () | 42 (36–49) | 0.003 | I () | 24 (19–29) | | Serum CEA | ≤30 ng/mL () | 40 (33–46) | 0.035 | >30 ng/mL () | 25 (20–30) | |
|
|
ECOG: Eastern Cooperative Oncology Group; CEA: carcinoembryonic antigen.
|